Taxol increases the amount and T cell-activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells

Cancer Research

Volumn 67, Issue 17, 2007, Pages 8378-8387

  Tsuda, Naotake ^a   Chang, David Z ^a   Mine, Takashi ^a,b   Efferson, Clay ^a,c   García Sastre, Adolfo ^d,e   Wang, Xinhui ^f   Ferrone, Soldano ^f   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Department of Microbiology ^*

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 96; INTERLEUKIN 12; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PACLITAXEL; PEPTIDE E75; PERFORIN; PHOSPHOPROTEIN; PROTEASOME; SCAVENGER RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPLASM; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; LYSOSOME; MITOSIS; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RIBOSOME; T LYMPHOCYTE ACTIVATION; UBIQUITINATION;

ANTIGEN-ANTIBODY COMPLEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-12; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MULTIPROTEIN COMPLEXES; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDE FRAGMENTS; POLYRIBOSOMES; RECEPTOR, ERBB-2; RIBOSOMES; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 34548583162     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0327     Document Type: Article

References (40)

1. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.
2. Coleman S, Clayton A, Mason MD, et al. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 2005;65:7000-6.
3. van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66:601-4.
4. Catic A, Collins C, Church GM, Ploegh HL. Preferred in vivo ubiquitination sites. Bioinformatics 2004;20:3302-7.
5. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
6. Wang SC, Lien HC, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-61.
7. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006;7:165-72.
8. Efferson CL, Tsuda N, Kawano K, et al. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol 2006;80:383-94.
9. Mason DE, Ek J, Peters EC, Harris JL. Substrate profiling of deubiquitin hydrolases with a positional scanning library and mass spectrometry. Biochemistry 2004;43:6535-44.
10. Efferson CL, Schickli J, Ko BK, et al. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. J Virol 2003;77:7411-24.
11. Palliser D, Guillen E, Ju M, Eisen HN. Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells. J Immunol 2005;174:1879-87.
12. Greenberg VL, Zimmer SG. Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 2005;24:4851-60.
13. Ahn HJ, Kim YS, Kim JU, et al. Mechanism of Taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 2004;91:1043-52.
14. + cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res 2005;65:2930-7.
15. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004;199:1607-18.
16. Boscardin SB, Hafalla JC, Masilamani RF, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006;203:599-606.
17. Fernandez J, Yaman I, Huang C, et al. Ribosome stalling regulates IRES-mediated translation in eukaryotes, a parallel to prokaryotic attenuation. Mol Cell 2005;17:405-16.
18. Richly H, Rape M, Braun S, et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005;120:73-84.
19. Schuberth C, Buchberger A. Membrane-bound Ubx2 recruits Cdc48 to ubiquitin ligases and their substrates to ensure efficient ER-associated protein degradation. Nat Cell Biol 2005;7:999-1006.
20. Hundley HA, Walter W, Bairstow S, Craig EA. Human Mpp11 J protein: ribosome-tethered molecular chaperones are ubiquitous. Science 2005;308:1032-4.
21. Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host-pathogen interface. Nat Immunol 2006;7:117-20.
22. Goodnow CC. Discriminating microbe from self suffers a double toll. Science 2006;312:1606-8.
23. Vollmer J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites with small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575-85.
24. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61.
25. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23:165-75.
26. Dehlin E, Wormington M, Korner CG, Wahle E. Cap-dependent deadenylation of mRNA. EMBO J 2000;19:1079-86.
27. Child SJ, Miller MK, Geballe AP. Translational control by an upstream open reading frame in the HER-2/neu transcript. J Biol Chem 1999;274:24335-41.
28. Doherty JK, Bond CT, Hua W, Adelman JP, Clinton GM. An alternative HER-2/neu transcript of 8 kb has an extended 3′UTR and displays increased stability in SKOV-3 ovarian carcinoma cells. Gynecol Oncol 1999;74:408-15.
29. Tsuda N, Kawano K, Efferson CL, Ioannides CG. Synthetic microRNA and double-stranded RNA targeting the 3′-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells. Int J Oncol 2005;27:1299-306.
30. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-9.
31. Abujarour RJ, Dalal S, Hanson PI, Draper RK. p97 is in a complex with cholera toxin and influences the transport of cholera toxin and related toxins to the cytoplasm. J Biol Chem 2005;280:15865-71.
32. Smith DC, Spooner RA, Watson PD, et al. Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 2006;7:379-93.
33. Shpanchenko OV, Zvereva MI, Ivanov PV, et al. Stepping transfer messenger RNA through the ribosome. J Biol Chem 2005;280:18368-74.
34. Adachi K, Lakka V, Zhao Y, Surrey S. Ubiquitylation of nascent globin chains in a cell-free system. J Biol Chem 2004;279:41767-74.
35. Krichevsky AM, Kosik KS. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 2001;32:683-96.
36. Li G, Xiang Y, Sabapathy K, Silverman RH. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004;279:1123-31.
37. Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005;201:1435-46.
38. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (Taxotere) for breast cancer. Clin Exp Rheumatol 2001;19:197-200.
39. De Angelis R, Bugatti L, Cerioni A, DelMedico P, Filosa G. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003;22:49-52.
40. Uchi H, Stan R, Turk MJ, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006;90:215-41.